Valneva and Instituto Butantan Announce Brazil Pilot Vaccination Strategy with Chikungunya Vaccine

Valneva and Instituto Butantan announce the start of a pilot vaccination strategy in Brazil using the single-dose chikungunya vaccine IXCHIQ. The campaign will cover ten strategically selected municipalities and aim for a 20-40% vaccination coverage rate. Valneva will provide up to 500,000 doses of IXCHIQ to support the program. The vaccine was approved in Brazil in April 2025 and marks the first global approval of a chikungunya vaccine in an endemic country. The pilot program aims to generate robust data on the vaccine's performance in real-world conditions.